Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Warfarin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions

NCT03234699
View directory record Official record
Conditions
Healthy
Interventions
Cenobamate, midazolam, Warfarin Pill, Omeprazole Pill, Bupropion Pill
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

NCT03359876
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

NCT02422589
View directory record Official record
Conditions
ALK-positive Advanced Tumors
Interventions
ceritinib, warfarin, midazolam
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Oral Vitamin K for Warfarin Associated Coagulopathy

NCT00143715
View directory record Official record
Conditions
Coagulation, Bleeding, Thrombosis
Interventions
Phytonadione (Vitamin K1)
Drug
Lead sponsor
St. Joseph's Healthcare Hamilton
Other
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Westminster, Colorado • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

NCT01133366
View directory record Official record
Conditions
Healthy
Interventions
warfarin sodium, mipomersen sodium; warfarin sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

NCT02072434
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Edoxaban, Warfarin, Enoxaparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
2,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

NCT00673439
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
fondaparinux, warfarin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

NCT00041938
View directory record Official record
Conditions
Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
Interventions
aspirin, Warfarin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
54
States / cities
Tucson, Arizona • Santa Clara, California • West Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 3 Interventional Results available

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

NCT04142658
View directory record Official record
Conditions
Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure
Interventions
Apixaban 5 MG, Apixaban 2.5 MG, Warfarin, On-X Aortic Mechanical Valve
Drug · Device
Lead sponsor
Artivion Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
62
States / cities
Tucson, Arizona • Little Rock, Arkansas • Loma Linda, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Withdrawn Early Phase 1 Interventional

Biological Effect of Warfarin on Pancreatic Cancer

NCT03536208
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Warfarin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

NCT01825876
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib, Warfarin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

NCT00412984
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
20,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
284
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin

NCT00321009
View directory record Official record
Conditions
Coronary Artery Disease, Acute Myocardial Infarction
Interventions
Enoxaparin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Denver, Colorado • Royal Oak, Michigan • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 2, 2006 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy

NCT00993200
View directory record Official record
Conditions
Blood Clotting
Interventions
warfarin pharmacogenetic dosing, Warfarin
Genetic · Drug
Lead sponsor
Robert Pendleton
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

NCT02376010
View directory record Official record
Conditions
Atherosclerosis
Interventions
rivaroxaban, Warfarin
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 84 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

NCT00129545
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
WATCHMAN Left Atrial Appendage Closure Technology, Warfarin
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
58
States / cities
Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)

NCT00070655
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
SR34006 (idraparinux sodium) Injection, vitamin K antagonist (warfarin or acenocoumarol) tablets
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Testing Strategies to Improving Warfarin Adherence

NCT00622102
View directory record Official record
Conditions
Atrial Fibrillation, Deep Venous Thrombosis, Dilated Cardiomyopathies
Interventions
Lottery arm (Lottery and Med-eMonitor), Non-Lottery (Med-eMonitor only)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study of Exercise in Patients With Leg Blood Clots

NCT00910364
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Exercise
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Withdrawn Not applicable Interventional

FFP Versus PCC in Intracranial Hemorrhage

NCT02429453
View directory record Official record
Conditions
Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
Interventions
Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma
Drug · Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting No phase listed Observational

Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)

NCT06844227
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
Not listed
Lead sponsor
McMaster University
Other
Eligibility
18 Years to 100 Years
Enrollment
1,780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Evanston, Illinois • Detroit, Michigan • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 17, 2026, 4:08 AM EDT